• The U.S. FDA is proposing issuing an order that would remove the oral decongestant phenylephrine from many over-the-counter cough and cold medicines as a review has found the drug ineffective.
• The agency said that a comprehensive evaluation examined data from decades ago used to support oral phenylephrine's initial approval as well as newer data. Other formulations of phenylephrine are not impacted.
• Oral phenylephrine is found in many popular OTC cough and cold remedies including Kenvue's (NYSE:KVUE) Sudafed, Procter & Gamble's (PG) DayQuil and NyQuil, and Haleon's (NYSE:HLN) Robitussin and Triaminic.
• The FDA's proposed order is not a surprise considering an advisory committee in September 2023 voted that oral phenylephrine lacks effectiveness.
• The following month, CVS Health (CVS) pulled products containing oral phenylephrine from its shelves.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.